Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Celergenus
Research Triangle Park, North Carolina, United Statescelergenus.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Celergenus is a biotechnology company focused on the development of next-generation gene therapies for rare genetic disorders, particularly neuromuscular diseases. The company utilizes proprietary adeno-associated virus (AAV) vector technology to deliver therapeutic genes, such as mini-dystrophin, to treat Duchenne Muscular Dystrophy (DMD). Founded by gene therapy pioneer Dr. Xiao Xiao, Celergenus aims to overcome the limitations of current treatments by optimizing vector potency and manufacturing scalability. Their research emphasizes high-efficiency gene delivery and long-term expression to improve patient outcomes in underserved populations.
- Therapeutic areas
- Rare Diseases
- Modalities
- Gene therapyBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on Celergenus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Celergenus.